Ironwood Pharma (IRWD) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update
November 2, 2017 8:05 AM EDTIronwood revenue grew 31% to $87 million in 3Q 2017 over 3Q 2016
LINZESS® (linaclotide) U.S. net sales increased 16% to $191 million and net profit increased 36% to $111 million in 3Q 2017 over 3Q 2016
Launched DUZALLO® (lesinurad and allopurinol), a once-daily fixed-dose combination treatment for patients with uncontrolled gout
Advanced innovative development candidates with positive IW-3718 Phase IIb trial results and initiation of IW-1973 Phase II trials in diabetic nephropathy and HFpEF
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
